Canakinumab (proposed)

( DrugBank: Canakinumab / KEGG DRUG: Canakinumab )

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
46	悪性関節リウマチ	11

46. 悪性関節リウマチ

臨床試験数 : 4,356 / 薬物数 : 2,567 - (DrugBank : 415) / 標的遺伝子数 : 192 - 標的パスウェイ数 : 228

trials per page:

Showing 1 to 10 of 11 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2007-000491-16-AT (EUCTR)	06/12/2007	05/04/2007	A 76-week open-label extension study to evaluate the efficacy, safety and tolerability of ACZ885 (an ...	A 76-week open-label extension study to evaluate the efficacy, safety and tolerability of ACZ885 (an ...	Rheumatoid Arthritis MedDRA version: 8.1;Level: LLT;Classification code 10039073;Term: Rheumatoid ar ...	Product Code: ACZ885 INN or Proposed INN: Canakinumab (proposed) Other descriptive name: ACZ885 Drug S ...	Novartis Pharma Services AG	NULL	Not Recruiting			Female: yes Male: yes	260		Germany;Spain;Austria
2	EUCTR2007-001665-15-NL (EUCTR)	09/11/2007	17/10/2007	A 54-week, phase II, multi-center, open-label extension study to evaluate the efficacy, safety and t ...	A 54-week, phase II, multi-center, open-label extension study to evaluate the efficacy, safety and t ...	Rheumatoid Arthritis MedDRA version: 8.1;Level: LLT;Classification code 10039073;Term: Rheumatoid ar ...	Product Code: ACZ885 INN or Proposed INN: Canakinumab (proposed) Other descriptive name: ACZ885 Drug S ...	Novartis Pharma Services AG	NULL	Not Recruiting			Female: yes Male: yes	179	Phase 2	Germany;Netherlands;Spain;Italy
3	EUCTR2007-001665-15-DE (EUCTR)	16/10/2007	30/07/2007	A 54-week, phase II, multi-center, open-label extension study to evaluate the efficacy, safety and t ...	A 54-week, phase II, multi-center, open-label extension study to evaluate the efficacy, safety and t ...	Rheumatoid Arthritis MedDRA version: 8.1;Level: LLT;Classification code 10039073;Term: Rheumatoid ar ...	Product Code: ACZ885 INN or Proposed INN: Canakinumab (proposed)	Novartis Pharma Services AG	NULL	Not Recruiting			Female: yes Male: yes	179	Phase 2	Germany;Netherlands;Spain;Italy
4	EUCTR2007-001665-15-ES (EUCTR)	14/09/2007	27/06/2007	Estudio de extensión abierto, multicéntrico, de fase II, de 54 semanas de duración, para evaluar la ...	Estudio de extensión abierto, multicéntrico, de fase II, de 54 semanas de duración, para evaluar la ...	Artritis Reumatoide MedDRA version: 8.1;Level: LLT;Classification code 10039073;Term: Rheumatoid art ...	Product Code: ACZ885 INN or Proposed INN: Canakinumab (proposed) Other descriptive name: ACZ885 Drug S ...	Novartis Farmaceutica S.A.	NULL	Not Recruiting			Female: yes Male: yes	179		Belgium;Spain;Netherlands;Germany;Italy
5	EUCTR2007-001665-15-BE (EUCTR)	05/09/2007	02/08/2007	A 54-week, phase II, multi-center, open-label extension study to evaluate the efficacy, safety and t ...	A 54-week, phase II, multi-center, open-label extension study to evaluate the efficacy, safety and t ...	Rheumatoid Arthritis MedDRA version: 8.1;Level: LLT;Classification code 10039073;Term: Rheumatoid ar ...	Product Code: ACZ885 INN or Proposed INN: Canakinumab (proposed) Other descriptive name: ACZ885 Drug S ...	Novartis Pharma Services AG	NULL	Not Recruiting			Female: yes Male: yes	179	Phase 2	Spain;Belgium;Netherlands;Germany;Italy
6	EUCTR2006-004666-14-DE (EUCTR)	17/07/2007	02/04/2007	An exploratory, open label pharmacokinetic – pharmacodynamic study to compare subcutaneous versus in ...	An exploratory, open label pharmacokinetic – pharmacodynamic study to compare subcutaneous versus in ...	Rheumatoid Arthritis MedDRA version: 8.1;Level: LLT;Classification code 10039073;Term: Rheumatoid ar ...	Product Code: ACZ885 INN or Proposed INN: Canakinumab (proposed) Other descriptive name: ACZ885 Drug S ...	Novartis Pharma Services AG	NULL	Not Recruiting			Female: yes Male: yes	32		Germany
7	EUCTR2007-000491-16-BE (EUCTR)	22/06/2007	04/05/2007	A 76-week open-label extension study to evaluate the efficacy, safety and tolerability of ACZ885 (an ...	A 76-week open-label extension study to evaluate the efficacy, safety and tolerability of ACZ885 (an ...	Rheumatoid Arthritis MedDRA version: 8.1;Level: LLT;Classification code 10039073;Term: Rheumatoid ar ...	Product Code: ACZ885 INN or Proposed INN: Canakinumab (proposed) Other descriptive name: ACZ885 Drug S ...	Novartis Pharma Services AG	NULL	Not Recruiting			Female: yes Male: yes			Spain;Belgium;Austria;Germany
8	EUCTR2007-000491-16-DE (EUCTR)	08/06/2007	22/03/2007	A 76-week open-label extension study to evaluate the efficacy, safety and tolerability of ACZ885 (an ...	A 76-week open-label extension study to evaluate the efficacy, safety and tolerability of ACZ885 (an ...	Rheumatoid Arthritis MedDRA version: 8.1;Level: LLT;Classification code 10039073;Term: Rheumatoid ar ...	Product Code: ACZ885 INN or Proposed INN: Canakinumab (proposed)	Novartis Pharma Services AG	NULL	Not Recruiting			Female: yes Male: yes	200		Germany;Spain;Austria
9	EUCTR2006-004666-14-BE (EUCTR)	04/06/2007	29/03/2007	An exploratory, open label pharmacokinetic – pharmacodynamic study to compare subcutaneous versus in ...	An exploratory, open label pharmacokinetic – pharmacodynamic study to compare subcutaneous versus in ...	Rheumatoid Arthritis MedDRA version: 8.1;Level: LLT;Classification code 10039073;Term: Rheumatoid ar ...	Product Code: ACZ885 INN or Proposed INN: Canakinumab (proposed) Other descriptive name: ACZ885 Drug S ...	Novartis Pharma Services AG	NULL	Not Recruiting			Female: yes Male: yes	32		Belgium;Germany
10	EUCTR2007-000491-16-ES (EUCTR)	30/04/2007	05/03/2007	Estudio de extensión abierto de 76 semanas de duración para evaluar la eficacia, seguridad y tolerab ...	Estudio de extensión abierto de 76 semanas de duración para evaluar la eficacia, seguridad y tolerab ...	Artritis Reumatoide MedDRA version: 8.1;Level: LLT;Classification code 10039073;Term: Rheumatoid art ...	Product Name: ACZ885 Product Code: ACZ885 INN or Proposed INN: Canakinumab (proposed) Other descriptive ...	Novartis Farmacéutica, S.A.	NULL	Not Recruiting			Female: yes Male: yes			Belgium;Spain;Austria;Germany

First Previous1 2Next Last